Related Experiment Videos

Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients form a defined population

G Sturfelt1, J Eskilsson, O Nived

  • 1Department of Rheumatology, University Hospital of Lund, Sweden.

Medicine
|July 1, 1992
PubMed

Insights

Systemic lupus erythematosus patients show increased cardiac issues, including valvular disease and myocardial infarction, linked to IgG anticardiolipin antibodies. Prolonged glucocorticoid use was also associated with these cardiac complications.

Area of Science:

  • Cardiology
  • Rheumatology
  • Immunology

Background:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease with potential multi-organ involvement.
  • Cardiac complications are a significant concern in SLE patients, impacting morbidity and mortality.

Purpose of the Study:

  • To investigate cardiac function in patients with SLE.
  • To explore the association between cardiac abnormalities and IgG anticardiolipin antibodies (IgG aCL).

Main Methods:

  • Prospective study of 101 SLE patients, with 75 undergoing detailed cardiac investigations.
  • Methods included echocardiography, Doppler cardiography, ECG (rest and exercise), and myocardial scintigraphy.
  • ELISA was used to determine IgG aCL levels.

Main Results:

  • 27% of patients had valvular disease, with 60% of these showing elevated IgG aCL (p<0.01).
  • 19% had pericardial effusion, and 16% had mild pulmonary hypertension, both associated with increased IgG aCL.
  • Myocardial infarction occurred in 7 patients, with prolonged glucocorticoid treatment linked to valvular abnormalities and myocardial infarction. Valvular abnormalities and IgG aCL were identified as risk factors for cerebral infarction.

Conclusions:

  • Cardiac involvement, including valvular disease and myocardial infarction, is prevalent in SLE patients.
  • Elevated IgG aCL is significantly associated with valvular disease and may indicate increased cardiovascular risk.
  • Glucocorticoid therapy and IgG aCL are potential risk factors for adverse cardiac and cerebrovascular events in SLE.

Related Concept Videos